Physician profile
Cheryl K Bauer-Olson
NPI 1871553313
$502.81
in general payments reported to CMS, 2019-2025
13 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.90 · 2022: $31.73 · 2023: $114 · 2024: $112 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $108.56 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $75.79 | 2023-2024 | Vraylar |
| Pfizer INC. | $59.38 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $43.00 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $42.57 | 2024-2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $41.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.77 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.91 | 2021 | |
| Astellas Pharma US INC | $18.14 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $17.36 | 2022 | |
| Alkermes, INC. | $13.88 | 2023 | Aristada, Lybalvi |
| Ultragenyx Pharmaceutical INC. | $13.70 | 2021 | |
| Exeltis, USA INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Bauer-Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.